BiotechTube
Xpamac

Xpamac

Budapest, Hungary· Est.
xpamac.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Xpamac is an early-stage biotech company offering cell line development services and technology to improve the manufacturing of complex biologics. Its core innovation is the XPAMAC Technology, which uses Mammalian Elongated Chromosomes (MEC) to enable stable, high-yield protein expression in CHO and HEK293 cells, aiming to solve manufacturing bottlenecks. Founded by venture capitalists and scientists from Szeged, the company is pre-revenue and actively seeking partnerships with biopharma firms and CDMOs to commercialize its platform.

Drug DeliverySmall Molecules

Technology Platform

Mammalian Elongated Chromosome (MEC) platform for stable, high-yield cell line development for therapeutic protein production. Also researching an Intracellular Protein Therapeutics (IPT) Platform for cytosolic delivery.

Opportunities

The rapidly expanding biologics market creates strong demand for technologies that improve manufacturing efficiency and yield.
Partnering with CDMOs offers a capital-light path to scale and validate the platform across multiple client projects.

Risk Factors

Technology faces validation risk against established cell line development methods in a competitive market.
As a pre-revenue startup, it is highly dependent on securing continued venture funding to reach commercial partnerships.

Competitive Landscape

Competes with established cell line development service providers and alternative gene integration technologies (e.g., transposon systems, CRISPR-based targeting). Differentiation hinges on demonstrating superior yield, stability, and speed compared to these incumbents.

More companies in Small Molecule Drugs →More companies in Hungary →